ArticleCNS neuroscience & therapeutics2026
LRP1 Activation Promotes Metabolic Reprogramming and Mrc1 Expression to Attenuate LPS-Induced Cognitive Deficits: An Integrated Omics Analysis.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimCentral insulin resistance and neuroinflammation act as synergistic drivers in the pathogenesis of cognitive decline. While the low-density lipoprotein receptor-related protein 1 (LRP1) is known to maintain blood-brain barrier integrity, its capacity to decouple the inflammation-metabolism axis remains underexplored. This study investigates whether activation of LRP1 can ameliorate LPS-induced cognitive deficits by recalibrating cerebral glucose metabolism.
methodsWe utilized an integrative approach combining behavioral phenotyping with targeted metabolomics and transcriptomics to dissect the neuroprotective mechanism of SP16, a selective LRP1 agonist. Cognitive dysfunction was modeled in mice via intracerebroventricular (i.c.v) LPS administration, followed by systemic intervention with intraperitoneally (i.p) injected SP16.
resultsSP16 treatment preserved cognitive function and prevented neuronal structural atrophy against the LPS injection. Mechanistically, LRP1 activation did more than suppress inflammation; it functionally modulated hippocampal insulin sensitivity and re-established redox homeostasis. Crucially, metabolomic profiling highlighted a restoration of glycolytic flux, centered on the normalization of fructose-1,6-bisphosphate (FBP) levels. This metabolic reprogramming coincided with the upregulation of the M2-like reparative marker, Mrc1.
conclusionOur findings identify LRP1 as a regulator that bridges metabolic health and immune resolution. By enforcing a metabolic shift via the FBP node, SP16 effectively guides microglia from a pro-inflammatory state toward tissue repair. Thus, honing in on SP16-mediated metabolic reprogramming presents an opportunity for a therapeutic intervention against neuroinflammation-associated cognitive impairment, offering a more nuanced alternative to broad-spectrum anti-inflammatories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.